High risk (B3) breast lesions paper. Reprinted from European Journal of Surgical Oncology, Vol 45, Issue 4, Forester N, et al, High risk (B3) breast lesions: What is the incidence of malignancy for individual lesion subtypes? A systematic review and meta-analysis. Pages 519-527, Copyright 2019, with permission from Elsevier.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Licensed from: https://www.sciencedirect.com/science/article/abs/pii/S0748798318320304
NeoSphere paper. Reprinted from The Lancet Oncology, Vol. 17, Issue 6, Gianni L, et al, 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Pages 791-800, Copyright 2016, with permission from Elsevier.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Licensed from: https://www.sciencedirect.com/science/article/abs/pii/S1470204516001637
Sloane DCIS paper. Reprinted from European Journal of Cancer, Volume 10, Thompson AM, et al, Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project. Pages 210-219, Copyright 2018, with permission from Elsevier.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Licensed from: https://www.sciencedirect.com/science/article/abs/pii/S0959804918309419